Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
|Webcasts|August 4, 2020
Manufacturing amorphous solid dispersions by spray-drying: scale-up approaches
Author(s)Lonza Pharma & Biotech
This webcast focuses on manufacturing aspects of amorphous spray-dried dispersions to enable successful scale-up and optimization of the process. An overview of spray drying and typical scale-up challenges will be presented along with a robust process development strategy to ensure critical-to-quality attributes are maintained. Tools and methodologies that enable rapid scale-up that is right the first time from clinical to commercial scale will also be highlighted. Live: Tuesday, Aug. 4, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after airing until Aug. 4, 2021 Register free
Register free:
Event Overview:
Spray-drying is a preferred process for manufacturing amorphous solid dispersions, which provide oral bioavailability enhancement for low-solubility small molecules. High permeability, low-solubility BCS Class II compounds are prevalent, representing approximately 70% of the new chemical entity pipeline, driving continued research and optimization of dispersion technology.
This webinar focuses on manufacturing aspects of amorphous spray-dried dispersions (SDDs) to enable successful scale-up and optimization of the process. An overview of spray drying and typical scale-up challenges will be presented along with a robust process development strategy to ensure critical-to-quality attributes are maintained. Tools and methodologies that enable rapid scale-up that is right the first time from clinical to commercial scale will also be highlighted.
In a scale-up case study of spray-dried Eudragit L100, a filament particle morphology was observed, leading to poor yields and very low bulk density. By controlling the formulation and process parameters, researchers identified a scale-independent process space where SDDs can be manufactured without filament formation at high product yields and with desired particle properties.
Key Learning Objectives:
- Process optimization of the manufacturing aspects of amorphous spray-dried dispersions
- Tools and methodologies for scale-up from clinical to commercial phases
- How to avoid string formation at high product yields and with desired particle properties
Speakers: Joel Wood, Product Development Engineer, Lonza Bend, OR
Kim Shepard, Ph.D., Associate Principal Engineer, Lonza Bend, OR
Time and date: US & Europe: Tuesday, Aug 4, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
Asia Pacific: Wednesday, Aug. 5, 2020 at 2pm Singapore | 2pm China | 3pm Japan | 3pm Korea
On demand available after airing until Aug. 4, 2021
Sponsor: Lonza Pharma & Biotech
Register free:
Related to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Trending on Pharmaceutical Technology
1
Risk-Based Life Cycle Management of Master Production and Control Records to Strengthen Data Integrity and GMP Inspection Readiness Part 2: Practical Considerations for CGMP Documentation Systems
2
PharmTech’s Weekly Roundup—September 25, 2026
3
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
4
CPHI Milan: USP Benchmarks Reshape Procurement Incentives
5